73 results on '"Maru, Dipen"'
Search Results
2. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target.
3. Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
4. Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer.
5. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
6. Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.
7. Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC.
8. Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer: A phase II trial of bintrafusp alfa in CMS4 metastatic CRC.
9. A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs).
10. ARID1A mutation to define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer.
11. Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).
12. Paratracheal lymph node metastasis in operable localized esophageal and gastroesophageal junction adenocarcinoma.
13. Association of TGF-β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer.
14. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients.
15. Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC).
16. The characteristics of ARID1A mutations in colorectal cancer.
17. The rate of novel actionable mutations in standard of care NGS panel testing in gastrointestinal malignancies.
18. Metabolic activity to predict clinical response and prognosis in esophageal adenocarcinoma patients treated with bimodality.
19. Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients.
20. Molecular characterization of TP53 mutations and copy number change in colorectal cancers.
21. Prognostic implications of TAMs in colorectal cancer hepatic metastases.
22. RAS heterogeneity as a prognostic marker in metastatic colorectal cancer.
23. Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC.
24. Outcomes in older patients with localized gastric adenocarcinoma treated preoperatively.
25. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy.
26. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts).
27. Is the neutrophil-lymphocyte ratio (NLR) a predictive and prognostic factor in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT)?
28. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.
29. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer.
30. Correlation of pretreatment p63-positive subtype of gastroesophageal adenocarcinoma (GEAC) with pathologic complete response (pathCR) in patients receiving preoperative chemoradiation.
31. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
32. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis.
33. Accuracy of EUS-FNA for distant regional lymph nodes in the initial staging of esophageal cancer (EC).
34. Proteomic features of colorectal cancer independently predict relapse-free survival.
35. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations.
36. Actionable locoregional failures (LRFs) after therapy of localized esophageal carcinoma (LEC): Surveillance strategies and their benefits.
37. Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated metastatic colorectal cancer (mCRC).
38. Multiple independent methods fail to confirm MET amplification rate reported in literature for metastatic colorectal cancer (mCRC).
39. Importance of Surveillance and Success of Salvage Strategies After Definitive Chemoradiation in Patients With Esophageal Cancer
40. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.
41. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience.
42. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC).
43. Effect of the distribution of lymph node metastases on outcomes for trimodality-eligible patients with esophageal and esophagogastric junction adenocarcinoma (EAC).
44. Distribution and timing of distant metastasis (DM) after definitive therapy for patients with esophageal and esophagogastric junction (E-EGJ) cancer.
45. Clinical parameters’ model for predicting distant metastasis (DM) following definitive therapy in patients with localized esophageal and esophagogastric junction (E-EGJ) cancer.
46. Correlation of pretreatment nuclear GLI-1 labeling indices (LIs) with initial SUV (iSUV) in esophageal cancer (EC) patients undergoing trimodality therapy (TMT): A potential pathway to esophageal preservation.
47. Association between KRAS mutation and lung metastasis in advanced colorectal cancer.
48. Locoregional Failure Rate After Preoperative Chemoradiation of Esophageal Adenocarcinoma and the Outcomes of Salvage Strategies
49. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation.
50. Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.